Chan Woo Kang

4-Hydroxybenzaldehyde (4-HBA) is a naturally occurring benzaldehyde and the major active constituent of Gastrodia elata. While recent studies have demonstrated metabolic effects of 4-HBA, little is known about the physiological role of 4-HBA in acute wound healing. Here, we investigated the effects and mechanisms of 4-HBA on acute wound healing. Using an in vitro approach, we found that 4-HBA significantly promoted keratinocyte cell migration and invasion by increasing focal adhesion kinase and

RET rearrangement is a newly identified oncogenic mutation in lung adenocarcinoma (LADC). Activity of dovitinib (TKI258), a potent inhibitor of FGFR, VEGFR, and PDGFR, in RET-rearranged LADC has not been reported. The aims of the study are to explore antitumor effects and mechanisms of acquired resistance of dovitinib in RET-rearranged LADC. Using structural modeling and in vitro analysis, we demonstrated that dovitinib induced cell-cycle arrest at G0-G1 phase and apoptosis by selective inhibiti

Abstract Olfactory marker protein (OMP) is a marker of olfactory receptor-mediated chemoreception, even outside the olfactory system. Here, we report that OMP expression in the pituitary gland plays a role in basal and thyrotropin-releasing hormone (TRH)-induced prolactin (PRL) production and secretion. We found that OMP was expressed in human and rodent pituitary glands, especially in PRL-secreting lactotrophs. OMP knockdown in GH4 rat pituitary cells increased PRL production and secretion via

Olfactory marker protein (OMP) is a marker of olfactory receptor-mediated chemoreception, even outside the olfactory system. Here, we report that OMP expression in the pituitary gland plays a role in basal and thyrotropin-releasing hormone (TRH)-induced prolactin (PRL) production and secretion. We found that OMP was expressed in human and rodent pituitary glands, especially in PRL-secreting lactotrophs. OMP knockdown in GH4 rat pituitary cells increased PRL production and secretion via extracell

Metformin is widely used as a first-line therapy for type 2 diabetes mellitus. However, the molecular mechanisms by which it modulates intestinal glucose metabolism remain incompletely defined. Here metformin was orally administered to male C57BL/6 mice, followed by intraperitoneal glucose tolerance testing and fluorine-18 fluorodeoxyglucose tracing to evaluate glucose homeostasis. To investigate changes in intestinal glucose metabolism, IEC6 and Caco-2 cell lines were used for in vitro analysis

Pituitary adenoma-induced excess endocrine growth hormone (GH) secretion can lead to breast cancer development and metastasis. Herein, we used an acromegaly mouse model to investigate the role of excess endocrine GH on triple-negative breast cancer (TNBC) growth and metastasis. Additionally, we aimed to elucidate the molecular mechanism of transcription factor 20 (TCF20)/nuclear factor erythroid 2-related factor 2 (NRF2) signaling-mediated aggressiveness and metastasis of TNBC. Excess endocrine

<div>Abstract<p><i>RET</i> rearrangement is a newly identified oncogenic mutation in lung adenocarcinoma (LADC). Activity of dovitinib (TKI258), a potent inhibitor of FGFR, VEGFR, and PDGFR, in <i>RET</i>-rearranged LADC has not been reported. The aims of the study are to explore antitumor effects and mechanisms of acquired resistance of dovitinib in <i>RET</i>-rearranged LADC. Using structural modeling and <i>in vitro</i> analysis, we

Abstract Disclosure: C. Kang: None. J. Oh: None. E. Wang: None. S. Lee: None. J. Nam: None. J. Hong: None. E. Lee: None. C. Ku: None. Background: Rosiglitazone, a synthetic peroxisome proliferator-activated receptor γ (PPAR γ) ligand, are used to treat type II diabetes. Over the last few years, PPAR γ has received much attention for its ability to exert variable tumors. Objective: The aim of this study is to investigate the anti-tumor effect of rosiglitazone on prolactin secreting pituitary aden

<p>Supplementary Figure 3B and C. Inhibition of FAK activity in LC-2/ad cells and LC-2/ad DR cells B, Western blot analysis of indicated markers in LC-2/ad and LC-2/ad DR cells after treated with 1mM of dovitinib (DO), dasatinib (DA), saracatinib (SA), or PF562,271 (PF) for 4hr. C, Western blot analysis of indicated markers in LC-/2ad and LC-2/ad DR cells after treated with indicated dose of dovitinib (DO) for 4hr.</p>

<p>Supplementary Figure 3A. Inhibition of FAK activity in LC-2/ad cells and LC-2/ad DR cells. A, MTT assays of LC-2/ad and LC-2/ad DR cells. Cells were treated with indicated dose of dovitinib, PF-52,271, or both for 72hr, and cell viability was determined using MTT. Means are derived from three replicate (n=3). Error bars indicate mean {plus minus} SE of three replicates.</p>

<p>Supplementary Table 1. Docking score of dovitinib, vandetanib, and sunitinib against RET kinase.</p>

<p>Supplementary Figure 1. Supplementary Figure S1. Dovitinib inhibits RET kinase and its downstream signaling in lung cancer cells harboring RET rearrangement A, Western blot analysis of indicated markers in LC-2/ad cells after treated with indicated dose of dovitinib for 4hr. B. Western blot analysis to measure the levels of total FGFR3, FLT3, RET, and KIT upon siRNA treatment in LC-2/ad cell line. Cells were transfected with indicated siRNA for 48hr.</p>

<p>Supplementary Figure 2. Significant weight loss in LC-2/ad xenograft mice treated with vandetanib Mice bearing LC-2/ad cells were treated with vehicle only (Vehicle), dovitinib (DO 30mg/kg), dovitinib (DO 60mg/kg), or vandetanib (VA 50mg/kg) for 32days. Average percent change in body weight relative to initial body weight is shown. Error bars represent SEM **P < 0.001 for vehicle vs vandetanib 50mg/kg treatment group.</p>

<p>Supplementary Figure 2. Significant weight loss in LC-2/ad xenograft mice treated with vandetanib Mice bearing LC-2/ad cells were treated with vehicle only (Vehicle), dovitinib (DO 30mg/kg), dovitinib (DO 60mg/kg), or vandetanib (VA 50mg/kg) for 32days. Average percent change in body weight relative to initial body weight is shown. Error bars represent SEM **P < 0.001 for vehicle vs vandetanib 50mg/kg treatment group.</p>